Zebra Capital Management’s PTC Therapeutics PTCT Stock Holding History

Zebra Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$320K	Buy	+6,600	New	+$302K	1.6%	25
2022 Q4	–	Sell	-5,331	Closed	-$268K	–	82
2022 Q3	$268K	Buy	+5,331	New	+$261K	1.02%	42
2022 Q1	–	Sell	-7,855	Closed	-$313K	–	162
2021 Q4	$313K	Sell	7,855 -2,896	-27%	-$111K	0.5%	66
2021 Q3	$400K	Buy	+10,751	New	+$442K	0.48%	67

Other funds holding PTCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Zebra Capital Management's PTCT Position: Q1 2023 in Review

Zebra Capital Management opened a new position in PTC Therapeutics (PTCT) in Q1 2023: 6,600 shares worth $320K. The stake represents 1.6% of the portfolio and ranks #25 among its holdings. This is a return to the name: Zebra Capital Management previously reported a position in PTCT as recently as Q3 2022.

Zebra Capital Management first reported a position in PTCT in Q3 2021 and has held it in 4 quarters since. The position peaked at $400K in Q3 2021. 202 funds tracked by Wall St. Rank hold PTCT as of Q1 2023.

Zebra Capital Management held 6,600 shares of PTC Therapeutics worth $320K as of Q1 2023.
PTC Therapeutics was a new Zebra Capital Management position in Q1 2023.
PTC Therapeutics made up 1.6% of Zebra Capital Management's portfolio in Q1 2023, its #25 holding.
Zebra Capital Management first reported a position in PTC Therapeutics in Q3 2021 and has held it in 4 quarters since.
Zebra Capital Management's PTC Therapeutics position peaked at $400K in Q3 2021.
202 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2023.

Based on Zebra Capital Management's 13F filing for Q1 2023, filed 15 May 2023.